Genomic sequencing could expand newborn screening beyond biochemical tests

Routine newborn screening (NBS) has revolutionized early disease detection. However, traditional biochemical tests limit the range of conditions that can be identified at birth. Next generation sequencing is being explored as a complementary screening tool. A review was published in pediatric checkup It examines how next-generation sequencing can expand NBS from single-disease assays to genome-enabled, multi-disease screening approaches.

Every year, millions of newborns undergo routine screening as a preventive strategy to detect hereditary disorders before symptoms emerge. Newborn screening (NBS) programs have traditionally relied on biochemical markers to identify specific groups of treatable conditions, with remarkable success at the population level. However, as researchers are uncovering genetically driven diseases that manifest early in life, questions are emerging about whether existing screening frameworks are adequate for the genomic age.

To bridge this gap in early detection of genetic disease, Dr. Zhelan Huang of Fudan University Children’s Hospital, China, and Dr. Wenhao Zhou of Guangzhou Women and Children’s Medical Center have investigated the role of next-generation sequencing (NGS) in reshaping the landscape of NBS. Their study, published in pediatric checkup On January 6, 2026, the transition of NBS from biochemical assays for single disease to genome-enabled, multi-disease approaches was examined, while the challenges limiting the clinical implementation of genomic NBS (gNBS) were also discussed.

Dr. Zhou explains, “Traditional NBS methods are inherently hampered by their reliance on measurable biochemical abnormalities. While effective for disorders such as phenylketonuria or congenital hypothyroidism, many genetic diseases do not produce detectable metabolic signals during the neonatal period. As a result, affected infants appear healthy at birth but develop symptoms after irreversible damage has occurred.“Genetic screening therefore provides a straightforward strategy to uncover disease risk at its earliest possible stage.

GNBS uses NGS technology to analyze DNA obtained from the same dried blood spots previously collected for routine testing. Targeted gene panels, whole-exome sequencing, and whole-genome sequencing enable the simultaneous evaluation of multiple genes associated with hereditary disorders. This genomic approach can substantially extend the benefits of NGS by identifying conditions that are not detectable through traditional biochemical testing.

However, genomic screening introduces new complications. One of the most significant challenges is to interpret genetic variants of uncertain significance, whose clinical implications are unclear. Reporting such findings in a population-wide screening program may cause unnecessary anxiety to parents and raise ethical concerns. Therefore, GNBS requires careful selection of reportable genes and variants, particularly focusing on clinically actionable outcomes during childhood.

While traditional screening methods yield results within a few days, genomic sequencing may require weeks. This delay limits its usefulness to situations that require immediate intervention. Dr. Zhou adds, “A major research focus is to reduce the turnaround time for genetic testing through rapid whole-genome sequencing approaches, which are already being implemented in some critically ill infants. Although these methods are not yet used in routine population screening, continued efforts may broaden their application in the future.”

A major aspect that has been debated since its inception is the psychological and ethical dimensions associated with GNBS. Many parents view genomic screening favourably, while health care professionals remain more cautious, reflecting concerns about data interpretation, consent, and long-term data storage. Another complexity that arises is whether to report adult-onset conditions or incidental findings, which highlights the need for clear policy frameworks and access to genetic counseling support.

Dr. Zhou says, “DDriven by low cost, technological advancements, and supportive policy framework, GNBS are expected to gradually integrate with or evolve into a standardized tool for neonatal health care management. When used with traditional tests, it can help clarify ambiguous results and identify conditions beyond the detection limits of traditional methods.

While technical, ethical, and logistical challenges are shaping its implementation, genomic screening has the potential to refine the identification and management of congenitally inherited diseases. GNBS may enable a more accurate and informed approach to neonatal care, extending the benefits of screening beyond initial diagnosis to support long-term health planning.